BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 36814038)

  • 1. Comparison of outcomes in high-risk prostate cancer patients treated with low-/high-dose-rate brachytherapy plus external beam radiotherapy.
    Imai Y; Urabe F; Iwatani K; Nakazono M; Tashiro K; Honda M; Aoki M; Sato S; Takahashi H; Miki K; Kimura T
    Int J Clin Oncol; 2023 May; 28(5):698-706. PubMed ID: 36814038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose-rate brachytherapy monotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer.
    Yamazaki H; Masui K; Suzuki G; Nakamura S; Yamada K; Okihara K; Shiraishi T; Yoshida K; Kotsuma T; Tanaka E; Otani K; Yoshioka Y; Ogawa K
    Radiother Oncol; 2019 Mar; 132():162-170. PubMed ID: 30416045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose-rate brachytherapy with external beam radiotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer.
    Yamazaki H; Masui K; Suzuki G; Aibe N; Shimizu D; Kimoto T; Yamada K; Ueno A; Matsugasumi T; Yamada Y; Shiraishi T; Fujihara A; Okihara K; Yoshida K; Nakamura S
    Sci Rep; 2021 Mar; 11(1):6165. PubMed ID: 33731856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis.
    Smith GD; Pickles T; Crook J; Martin AG; Vigneault E; Cury FL; Morris J; Catton C; Lukka H; Warner A; Yang Y; Rodrigues G
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):505-16. PubMed ID: 25596107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-reported outcomes after Low-dose-rate versus High-dose-rate brachytherapy boost in combination with external beam radiation for intermediate and high risk prostate cancer.
    Dhere VR; Fischer-Valuck BW; Goyal S; Liu Y; Morgan TM; Ghavidel E; Moghanaki DM; Hershatter BW; Patel PR; Jani AB; Godette KD; Rossi PJ; Patel SA
    Brachytherapy; 2021; 20(6):1130-1138. PubMed ID: 34417136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Image-Guided Intensity-Modulated Radiotherapy and Low-dose Rate Brachytherapy with or without External Beam Radiotherapy in Patients with Localized Prostate Cancer.
    Tsubokura T; Yamazaki H; Masui K; Sasaki N; Shimizu D; Suzuki G; Nakamura S; Yamada K; Okihara K; Shiraishi T; Yoshida K; Nishikawa T; Okabe H
    Sci Rep; 2018 Jul; 8(1):10538. PubMed ID: 30002393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Five-year biochemical recurrence-free and overall survival following high-dose-rate brachytherapy with additional external beam or radical prostatectomy in patients with clinically localized prostate cancer.
    Boehm K; Schiffmann J; Tian Z; Lesmana H; Larcher A; Mandel P; Karakiewicz PI; Graefen M; Schwarz R; Krüll A; Tilki D
    Urol Oncol; 2016 Mar; 34(3):119.e11-8. PubMed ID: 26602027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvage brachytherapy for locally-recurrent prostate cancer after radiation therapy: A comparison of efficacy and toxicity outcomes with high-dose rate and low-dose rate brachytherapy.
    Henríquez López I; González-San Segundo C; Vegas JO; Gutierrez C; Hervas A; Cabeza Rodriguez MÁ; Valero Albarrán J; Rodríguez Villalba S; Álvarez Gonzalez A; Sancho Pardo G; Zapatero A; Álvaro PC
    Radiother Oncol; 2019 Dec; 141():156-163. PubMed ID: 31570236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer.
    Mohammed N; Kestin L; Ghilezan M; Krauss D; Vicini F; Brabbins D; Gustafson G; Ye H; Martinez A
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):204-12. PubMed ID: 21167653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort.
    Wedde TB; Småstuen MC; Brabrand S; Fosså SD; Kaasa S; Tafjord G; Russnes KM; Hellebust TP; Lilleby W
    Radiother Oncol; 2019 Mar; 132():211-217. PubMed ID: 30389241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the outcome and morbidity for localized or locally advanced prostate cancer treated by high-dose-rate brachytherapy plus external beam radiotherapy (EBRT) versus EBRT alone.
    Fang FM; Wang YM; Wang CJ; Huang HY; Chiang PH
    Jpn J Clin Oncol; 2008 Jul; 38(7):474-9. PubMed ID: 18621848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
    Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancer.
    King MT; Yang DD; Muralidhar V; Mahal B; Butler S; Devlin PM; Lee LJ; Mouw KW; Martin NM; D'Amico AV; Nguyen PL; Orio PF
    Brachytherapy; 2019; 18(2):186-191. PubMed ID: 30638912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Propensity score-matched analysis comparing dose-escalated intensity-modulated radiation therapy versus external beam radiation therapy plus high-dose-rate brachytherapy for localized prostate cancer.
    Tamihardja J; Lawrenz I; Lutyj P; Weick S; Guckenberger M; Polat B; Flentje M
    Strahlenther Onkol; 2022 Aug; 198(8):735-743. PubMed ID: 35551434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcomes analysis of low-dose-rate brachytherapy in clinically T3 high-risk prostate cancer.
    Agarwal M; Chhabra AM; Amin N; Braccioforte MH; Molitoris JK; Moran BJ
    Brachytherapy; 2018; 17(6):882-887. PubMed ID: 30143400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time Course and Accumulated Risk of Severe Urinary Adverse Events After High- Versus Low-Dose-Rate Prostate Brachytherapy With or Without External Beam Radiation Therapy.
    Tward JD; Jarosek S; Chu H; Thorpe C; Shrieve DC; Elliott S
    Int J Radiat Oncol Biol Phys; 2016 Aug; 95(5):1443-1453. PubMed ID: 27325475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose rate brachytherapy for men with localized prostate cancer.
    Peinemann F; Grouven U; Hemkens LG; Bartel C; Borchers H; Pinkawa M; Heidenreich A; Sauerland S
    Cochrane Database Syst Rev; 2011 Jul; (7):CD008871. PubMed ID: 21735436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic significance of the clinical T stage and Grade Group in patients with locally advanced prostate cancer treated via high-dose-rate brachytherapy and external beam radiation.
    Kadena S; Urabe F; Iwatani K; Suzuki H; Imai Y; Tashiro K; Tsuzuki S; Honda M; Koike Y; Shimomura T; Aoki M; Sato S; Takahashi H; Miki K; Kimura T
    Int J Clin Oncol; 2023 Aug; 28(8):1092-1100. PubMed ID: 37227547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative analysis between low-dose-rate brachytherapy and external beam radiation therapy for low- and intermediate-risk prostate cancer in Asian men.
    Li Y; Chan Kong Ngai T; Zhou S; Yap Haw Hwong J; Pang Pei Ping E; Ong Li Kuan A; Wang Lian Chek M; Chua Lee Kiang M; Looi WS; Nei WL; Chua ET; On WLK; Tan Wee Kiat T; Yuen Shyi Peng J; Tuan Kit Loong J
    Acta Oncol; 2021 Oct; 60(10):1291-1295. PubMed ID: 34259123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes of patients with localized and locally advanced prostate cancer undergoing high-dose-rate brachytherapy with external-beam radiotherapy at our institute.
    Makino T; Mizokami A; Namiki M
    Anticancer Res; 2015 Mar; 35(3):1723-8. PubMed ID: 25750334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.